These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22031512)

  • 1. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.
    Braun D; Kim TD; le Coutre P; Köhrle J; Hershman JM; Schweizer U
    J Clin Endocrinol Metab; 2012 Jan; 97(1):E100-5. PubMed ID: 22031512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient Activation of Pathogenic ΔPhe501 Mutation in Monocarboxylate Transporter 8 by Chemical and Pharmacological Chaperones.
    Braun D; Schweizer U
    Endocrinology; 2015 Dec; 156(12):4720-30. PubMed ID: 26368820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid hormone transport by the human monocarboxylate transporter 8 and its rate-limiting role in intracellular metabolism.
    Friesema EC; Kuiper GG; Jansen J; Visser TJ; Kester MH
    Mol Endocrinol; 2006 Nov; 20(11):2761-72. PubMed ID: 16887882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
    D'Cunha R; Bae S; Murry DJ; An G
    Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surface translocation and tri-iodothyronine uptake of mutant MCT8 proteins are cell type-dependent.
    Kinne A; Roth S; Biebermann H; Köhrle J; Grüters A; Schweizer U
    J Mol Endocrinol; 2009 Dec; 43(6):263-71. PubMed ID: 19648159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1.
    Omote S; Matsuoka N; Arakawa H; Nakanishi T; Tamai I
    Sci Rep; 2018 Jun; 8(1):9237. PubMed ID: 29915248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a nonradioactive assay for high throughput screening for inhibition of thyroid hormone uptake via the transmembrane transporter MCT8.
    Dong H; Wade MG
    Toxicol In Vitro; 2017 Apr; 40():234-242. PubMed ID: 28119167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain and in primary brain cells.
    Braun D; Kinne A; Bräuer AU; Sapin R; Klein MO; Köhrle J; Wirth EK; Schweizer U
    Glia; 2011 Mar; 59(3):463-71. PubMed ID: 21264952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine deficiency up-regulates monocarboxylate transporter 8 expression of mouse thyroid gland.
    Hu Z; Zhuo X; Shi Y; Liu X; Yuan J; Li L; Sun Y
    Chin Med J (Engl); 2014; 127(23):4071-6. PubMed ID: 25430451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silychristin, a Flavonolignan Derived From the Milk Thistle, Is a Potent Inhibitor of the Thyroid Hormone Transporter MCT8.
    Johannes J; Jayarama-Naidu R; Meyer F; Wirth EK; Schweizer U; Schomburg L; Köhrle J; Renko K
    Endocrinology; 2016 Apr; 157(4):1694-701. PubMed ID: 26910310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocarboxylate transporter 8 deficiency: altered thyroid morphology and persistent high triiodothyronine/thyroxine ratio after thyroidectomy.
    Wirth EK; Sheu SY; Chiu-Ugalde J; Sapin R; Klein MO; Mossbrugger I; Quintanilla-Martinez L; de Angelis MH; Krude H; Riebel T; Rothe K; Köhrle J; Schmid KW; Schweizer U; Grüters A
    Eur J Endocrinol; 2011 Oct; 165(4):555-61. PubMed ID: 21813593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between single nucleotide polymorphisms in thyroid hormone transporter genes (MCT8, MCT10 and OATP1C1) and circulating thyroid hormones.
    Roef GL; Rietzschel ER; De Meyer T; Bekaert S; De Buyzere ML; Van daele C; Toye K; Kaufman JM; Taes YE
    Clin Chim Acta; 2013 Oct; 425():227-32. PubMed ID: 23978482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential molecular determinants for thyroid hormone transport and first structural implications for monocarboxylate transporter 8.
    Kinne A; Kleinau G; Hoefig CS; Grüters A; Köhrle J; Krause G; Schweizer U
    J Biol Chem; 2010 Sep; 285(36):28054-63. PubMed ID: 20628049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for drugs potentially interfering with MCT8-mediated T
    Di Cosmo C; De Marco G; Agretti P; Ferrarini E; Dimida A; Falcetta P; Benvenga S; Vitti P; Tonacchera M
    J Endocrinol Invest; 2022 Apr; 45(4):803-814. PubMed ID: 34850364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in MCT8 in patients with Allan-Herndon-Dudley-syndrome affecting its cellular distribution.
    Kersseboom S; Kremers GJ; Friesema EC; Visser WE; Klootwijk W; Peeters RP; Visser TJ
    Mol Endocrinol; 2013 May; 27(5):801-13. PubMed ID: 23550058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
    Will Y; Dykens JA; Nadanaciva S; Hirakawa B; Jamieson J; Marroquin LD; Hynes J; Patyna S; Jessen BA
    Toxicol Sci; 2008 Nov; 106(1):153-61. PubMed ID: 18664550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid hormone transport by monocarboxylate transporters.
    Visser WE; Friesema EC; Jansen J; Visser TJ
    Best Pract Res Clin Endocrinol Metab; 2007 Jun; 21(2):223-36. PubMed ID: 17574005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Chemical Chaperones on Thyroid Hormone Transport by MCT8 Mutants in Patient-Derived Fibroblasts.
    Groeneweg S; van den Berge A; Meima ME; Peeters RP; Visser TJ; Visser WE
    Endocrinology; 2018 Mar; 159(3):1290-1302. PubMed ID: 29309566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
    Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
    Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.